-
1.发明申请Compounds and methods for treatment of amyloid-beta-peptide related disorders 审中-公开用于治疗淀粉样蛋白-β-肽相关病症的化合物和方法公开(公告)号：US20090118282A1
公开(公告)日：2009-05-07
申请号：US11989024
申请日：2006-07-21
IPC分类号： A61K31/4709 , C07D401/12 , C07D413/12 , C07D215/36 , A61P25/28 , A61K31/47 , C07D471/04 , A61K31/5377
CPC分类号： C07D215/36 , C07D401/12
摘要： The present invention relates to compounds, preparation and uses thereof, particularly in the pharmaceutical industry. The present invention discloses novel compounds more particularly useful for the treatment of Alzheimer's disease and other similar diseases, and more specifically the inventive compounds modulate (in particular, inhibit) the level of amyloid-β peptide (Aβ) exhibited by cells or tissues; Aβ peptide is a major component of the amyloid plaques found in the brains of Alzheimer's sufferers. This invention also relates the use of these inhibitors to prevent, treat or ameliorate the symptoms of Alzheimer's disease or any Amyloid-β-Peptide Related Disorder.
摘要翻译： 本发明涉及化合物，其制备和用途，特别是在制药工业中。 本发明公开了更特别可用于治疗阿尔茨海默病和其他类似疾病的新化合物，更具体地说，本发明化合物调节（特别是抑制）细胞或组织表现的淀粉样蛋白-β肽（Abeta）的水平; Abeta肽是阿尔茨海默氏症患者大脑中发现的淀粉样蛋白斑的主要成分。 本发明还涉及这些抑制剂用于预防，治疗或改善阿尔茨海默病或任何淀粉样蛋白-β-肽相关疾病症状的用途。
-
2.发明申请Method involving pde4, compositions, and the screening thereof, for the treatment of degenerative ocular pathologies 失效涉及pde4，组合物及其筛选的方法，用于治疗退行性眼病公开(公告)号：US20060241062A1
公开(公告)日：2006-10-26
申请号：US10541503
申请日：2004-02-18
IPC分类号： A61K31/7056 , A61K31/4745
CPC分类号： A61K31/437 , A61K31/444 , A61K31/706
摘要： The invention relates to the field of biology, genetics and medicine. In particular, the invention relates to novel methods for the detection, characterization and/or treatment (or management) of neurodegenerative pathologies. The invention also relates to methods for the identification or screening of compounds active in the aforementioned pathologies. The invention further relates to the compounds, genes, cells, plasmids or compositions which are used to carry out said methods. In particular, the invention is based on the identification of the role of phosphodiesterase 4B, the peripheral benzodiazepine receptor (PBR) and GABA receptors of the type GABA(A) in neurodegenerative pathologies and describes the use of same as therapeutic, diagnostic or experimental markers or targets for said disorders.
摘要翻译： 本发明涉及生物学，遗传学和医学领域。 特别地，本发明涉及神经变性病理学的检测，表征和/或治疗（或治疗）的新方法。 本发明还涉及用于鉴定或筛选在上述病理学中有活性的化合物的方法。 本发明还涉及用于实施所述方法的化合物，基因，细胞，质粒或组合物。 特别地，本发明基于在神经变性病理学中鉴定磷酸二酯酶4B，外周苯并二氮杂受体（PBR）和GABA（A）类型的GABA受体的作用，并描述了其用于治疗，诊断或实验标记 或所述疾病的靶标。
-
公开(公告)号：US20050043319A1
公开(公告)日：2005-02-24
申请号：US10857455
申请日：2004-06-01
IPC分类号： A61K31/00 , C12Q1/44 , C12Q1/68 , A61K31/519 , A61K31/522
CPC分类号： C12Q1/44 , A61K31/00 , C12Q1/6883 , C12Q2600/158
摘要： The present invention relates to the fields of biology, genetics and medicine. In particular it concerns new methods for the detection, characterisation and/or treatment (or management) of neurodegenerative diseases, particularly amyotrophic lateral sclerosis. The invention equally concerns methods for identifying or screening compounds active in these diseases. The invention further concerns the compounds, genes, cells, plasmids or compositions useful for implementing the hereinabove methods. In particular, the invention describes the role of PDE4B in these diseases and its use as a therapeutic, diagnostic or experimental target.
摘要翻译： 本发明涉及生物学，遗传学和医学领域。 特别地，它涉及用于神经变性疾病，特别是肌萎缩性侧索硬化症的检测，表征和/或治疗（或治疗）的新方法。 本发明同样涉及用于鉴定或筛选在这些疾病中活跃的化合物的方法。 本发明还涉及可用于实施上述方法的化合物，基因，细胞，质粒或组合物。 特别地，本发明描述了PDE4B在这些疾病中的作用及其作为治疗，诊断或实验目标的用途。
-
公开(公告)号：US20050009030A1
公开(公告)日：2005-01-13
申请号：US10502754
申请日：2003-03-25
IPC分类号： G01N33/50 , A61K31/00 , A61K31/7088 , A61P25/00 , C12N15/09 , C12Q1/02 , C12Q1/34 , C12Q1/68 , G01N33/15 , G01N33/53 , G01N33/566
CPC分类号： A61K31/00 , A61K31/7088 , C12Q1/6883 , C12Q2600/156
摘要： The present invention concerns the field of biology, genetics and medicine. It particularly pertains to new methods for detecting, characterising and/or treating neurodegenerative diseases, particularly amyotrophic lateral sclerosis. The invention also pertains to methods for identifying or screening for compounds active in these diseases. The invention also relates to the compounds, genes, cells, plasmids or compositions useful for implementing said methods. The invention particularly describes the role of the histone deacetylases, and particularly histone deacetylase 2, in these diseases and its use as a therapeutic, diagnostic or experimental target.
摘要翻译： 本发明涉及生物学，遗传学和医学领域。 它特别涉及用于检测，表征和/或治疗神经变性疾病，特别是肌萎缩性侧索硬化的新方法。 本发明还涉及鉴定或筛选这些疾病中活性物质的方法。 本发明还涉及可用于实施所述方法的化合物，基因，细胞，质粒或组合物。 本发明特别描述了组蛋白脱乙酰酶，特别是组蛋白脱乙酰酶2在这些疾病中的作用及其作为治疗，诊断或实验目标的用途。
-
公开(公告)号：US06251590B1
公开(公告)日：2001-06-26
申请号：US09046920
申请日：1998-03-24
IPC分类号： C12Q168
CPC分类号： C12Q1/6809 , C12Q1/6827 , C12Q1/6837 , C12Q2539/105 , C12Q2537/113 , C12Q2521/301 , C12Q2565/501
摘要： The present invention is directed to a method for identifying and/or cloning within a biological sample alternatively spliced nucleic acid regions ocurring between two physiological conditions, comprising hybridizing RNA derived from a test condition with cDNA derived from the standard condition and further identifying and/or cloning nucleic acids corresponding to alternative forms of splicing.
摘要翻译： 本发明涉及用于鉴定和/或克隆在两个生理条件之间的可变剪接的核酸区域的生物样品中的克隆方法，包括将来自测试条件的RNA与衍生自标准条件的cDNA杂交，并进一步鉴定和/或 对应于替代形式的剪接的克隆核酸。
-
6.发明授权Methods involving PDE4, compositions, and the screening thereof, for the treatment of degenerative ocular pathologies 失效涉及PDE4，组合物及其筛选的方法用于治疗退行性眼病公开(公告)号：US07872015B2
公开(公告)日：2011-01-18
申请号：US10541503
申请日：2004-02-18
IPC分类号： A01N43/42 , A01N43/40 , A01N43/56 , A61K31/44 , A61K31/415
CPC分类号： A61K31/437 , A61K31/444 , A61K31/706
摘要： The invention relates to the field of biology, genetics and medicine. In particular, the invention relates to novel methods for the detection, characterization and/or treatment (or management) of neurodegenerative pathologies. The invention also relates to methods for the identification or screening of compounds active in the aforementioned pathologies. The invention further relates to the compounds, genes, cells, plasmids or compositions which are used to carry out said methods. In particular, the invention is based on the identification of the role of phosphodiesterase 4B, the peripheral benzodiazepine receptor (PBR) and GABA receptors of the type GABA(A) in neurodegenerative pathologies and describes the use of same as therapeutic, diagnostic or experimental markers or targets for said disorders.
摘要翻译： 本发明涉及生物学，遗传学和医学领域。 特别地，本发明涉及神经变性病理学的检测，表征和/或治疗（或治疗）的新方法。 本发明还涉及用于鉴定或筛选在上述病症中活性的化合物的方法。 本发明还涉及用于实施所述方法的化合物，基因，细胞，质粒或组合物。 特别地，本发明基于在神经变性病理学中鉴定磷酸二酯酶4B，外周苯并二氮杂受体（PBR）和GABA（A）类型的GABA受体的作用，并描述了其用于治疗，诊断或实验标记 或所述疾病的靶标。
-
公开(公告)号：US20100055682A1
公开(公告)日：2010-03-04
申请号：US12227374
申请日：2007-05-14
IPC分类号： C12Q1/68 , C07H21/02 , C07D219/08 , C07D211/06 , C07C271/44
CPC分类号： C12Q1/6883 , C12Q1/6806 , C12Q2600/158
摘要： This application concerns methods and compositions that can be used for detecting the Alzheimer disease in mammals, particularly in humans. It describes in particular serum markers for Alzheimer's disease and the way they are used for diagnostic procedures. It also concerns tools and/or kits that can be used for applying these procedures (reagents, probes, primers, antibodies, chips, cells, etc.) with the preparation thereof and the way to use them. The invention can be used to detect the presence or the progression of Alzheimer illness in mammals, including at early stages of the disease.
摘要翻译： 本申请涉及可用于检测哺乳动物，特别是人类中的阿尔茨海默病的方法和组合物。 它特别描述了阿尔茨海默病的血清标志物及其用于诊断程序的方法。 它还涉及可用于应用这些程序（试剂，探针，引物，抗体，芯片，细胞等）及其使用方法的工具和/或试剂盒。 本发明可用于检测哺乳动物中阿尔茨海默病的存在或进展，包括在疾病的早期阶段。
-
公开(公告)号：US20070027146A1
公开(公告)日：2007-02-01
申请号：US11190070
申请日：2005-07-27
IPC分类号： A61K31/541 , A61K31/5377 , A61K31/496 , A61K31/4709
CPC分类号： A61K31/5375 , A61K31/4709 , A61K31/496 , A61K31/541
摘要： The invention relates to compositions and methods for treating nervous disorders. More particularly, the invention relates to methods of treating amyloïd beta peptide-related disorders, particularly Alzheimer's disease, using Rac1 inhibitors. The invention may be used in mammalian subjects, particularly human subjects, at various stages of the disease, including disease onset. The invention also provides methods of producing, identifying, selecting or optimising compounds for use in the treatment of amyloïd beta peptide-related disorders, based on a determination of the ability of a test compound to inhibit Rac1.
摘要翻译： 本发明涉及用于治疗神经障碍的组合物和方法。 更具体地，本发明涉及使用Rac1抑制剂治疗淀粉样肽相关病症，特别是阿尔茨海默氏病的方法。 本发明可用于哺乳动物受试者，特别是人类受试者，在疾病的各个阶段，包括发病。 本发明还提供了基于测定化合物抑制Rac1的能力的测定来制备，鉴定，选择或优化化合物用于治疗淀粉样肽相关病症的方法。
-
公开(公告)号：USRE37952E1
公开(公告)日：2002-12-31
申请号：US09641640
申请日：2000-08-15
申请人： Fabien Schweighoffer , Bruno Tocque
发明人： Fabien Schweighoffer , Bruno Tocque
IPC分类号： C07H2104
CPC分类号： C07K14/475 , A61K38/00 , C07K14/4705
摘要： The present invention relates to the Grb3-3 protein, nucleotide sequence encoding this protein, and variants thereof, such as antisense sequences. The invention further relates to vectors comprising these sequences and to methods for inducing cell death.
摘要翻译： 本发明涉及Grb3-3蛋白，编码该蛋白质的核苷酸序列及其变体，如反义序列。 本发明还涉及包含这些序列的载体和诱导细胞死亡的方法。
-
公开(公告)号：US20100144555A1
公开(公告)日：2010-06-10
申请号：US12641194
申请日：2009-12-17
CPC分类号： C12N15/1072 , C12Q1/6809 , C12Q1/6886 , C12Q2600/106 , C12Q2600/136 , C12Q2600/142 , C12Q2539/105 , C12Q2565/501 , C12Q2537/113 , C12Q2521/301
摘要： The invention concerns a method for identifying and/or cloning nucleic acid regions representing qualitative differences associated with alternative splicing events and/or with insertions, deletions located in RNA transcribed genome regions, between two physiological situations, comprising either hybridization of RNA derived from the test situation with cDNA's derived from the reference situation and/or reciprocally, or double-strand hybridization of cDNA derived from the test situation with cDNA's derived from the reference situation; and identifying and/or cloning nucleic acids representing qualitative differences. The invention also concerns compositions or banks of nucleic acids representing qualitative differences between two physiological situations, obtainable by the above method, and their use as probe, for identifying genes or molecules of interest, or still for example in methods of pharmacogenomics, and profiling of molecules relative to their therapeutic and/or toxic effects. The invention further concerns the use of dysregulation of splicing RNA as markers for predicting molecule toxicity and/or efficacy, and as markers in pharmacogenomics.
摘要翻译： 本发明涉及用于鉴定和/或克隆代表与选择性剪接事件相关的定性差异的核酸区域的方法和/或在两个生理情境之间的位于RNA转录基因组区域中的插入，缺失的方法，其包括衍生自测试的RNA的杂交 来自参考情况的cDNA的情况和/或来自测试情况的cDNA的双链杂交和/或来自参考情况的cDNA的双链杂交; 以及鉴定和/或克隆代表定性差异的核酸。 本发明还涉及表示通过上述方法获得的两种生理情况之间的定性差异的核酸组合物或组，以及它们作为探针的用途，用于鉴定感兴趣的基因或分子，或者仍然例如在药物基因组学的方法中，以及 分子相对于其治疗和/或毒性作用。 本发明还涉及使用拼接RNA的调节作为用于预测分子毒性和/或功效的标记物，以及作为药物基因组学中的标记物。
-
-
-
-
-
-
-
-
-
搜索结果
35 条记录 (耗时 0.018 秒)
